References

Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer

10.1158/1078-0432.ccr-13-1333 · 2016 · External reference

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

10.1002/path.2913 · 2011 · External reference

Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome

10.1038/ng.1004 · 2011 · External reference

IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas

10.1186/s13569-017-0074-6 · 2017 · External reference

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations

10.1007/s00401-021-02291-6 · 2021 · External reference

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

10.1038/nature08617 · 2009 · External reference

The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization

10.1074/jbc.m112.435495 · 2013 · External reference

D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma

10.1186/2051-5960-2-19 · 2014 · External reference

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases

10.1016/j.ccr.2010.12.014 · 2011 · External reference

Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling

10.1016/j.tcb.2017.06.002 · 2017 · External reference

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma

10.1158/1078-0432.ccr-24-4128 · 2025 · External reference

Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial

10.1038/s41467-026-68716-6 · 2026 · External reference

Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma

10.1200/jco.19.03327 · 2020 · External reference

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

10.1056/nejmoa2304194 · 2023 · External reference

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial

10.1001/jamaoncol.2021.3836 · 2021 · External reference

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

10.1056/nejmoa1716984 · 2018 · External reference

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML

10.1182/bloodadvances.2020001503 · 2020 · External reference

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma

10.1200/jco.19.02492 · 2020 · External reference

IDH Mutations in Chondrosarcoma: Case Closed or Not?

10.3390/cancers15143603 · 2023 · External reference

IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors

10.1158/1078-0432.ccr-17-2796 · 2018 · External reference

Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation

10.1093/neuonc/nos261 · 2013 · External reference

IDH1(R132H) mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of the oxygenation status

10.1016/j.radonc.2015.08.007 · 2015 · External reference

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity

10.1126/scitranslmed.aal2463 · 2017 · External reference

Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas

10.1126/sciadv.aaz3221 · 2020 · External reference

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

10.1038/nm.3788 · 2015 · External reference

Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL

10.1038/s41467-017-00984-9 · 2017 · External reference

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma

10.1038/s41389-018-0084-0 · 2018 · External reference

Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes

10.1186/s13569-019-0119-0 · 2019 · External reference

Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status

10.3390/cancers11121918 · 2019 · External reference

Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model

10.1097/corr.0000000000002483 · 2023 · External reference

A new human chondrosarcoma cell line (OUMS-27) that maintains chondrocytic differentiation

10.1002/(sici)1097-0215(19980911)77:6<854::aid-ijc10>3.0.co;2-1 · 1998 · External reference

Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma

10.3390/cancers12123589 · 2020 · External reference

IDH mutation impairs histone demethylation and results in a block to cell differentiation

10.1038/nature10860 · 2012 · External reference

Measurement of urinary D- and L-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatography-tandem mass spectrometry after derivatization with diacetyl-L-tartaric anhydride

10.1373/clinchem.2004.033399 · 2004 · External reference

Establishment and characterization of a continuous human chondrosarcoma cell line, ch-2879: comparative histologic and genetic studies with its tumor of origin

10.1097/01.lab.0000073131.34648.ea · 2003 · External reference

Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities

10.1186/s40170-018-0177-4 · 2018 · External reference

Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial

10.1002/cncr.35755 · 2025 · External reference

A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors

2025 · External reference

Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

10.1158/2767-9764.crc-22-0436 · 2023 · External reference

Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network

2024 · External reference

IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response

10.1126/scitranslmed.aaq1427 · 2019 · External reference

BCAT1 restricts alphaKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation

10.1038/nature24294 · 2017 · External reference

Loss of FBXW7 Correlates with Increased IDH1 Expression in Glioma and Enhances IDH1-Mutant Cancer Cell Sensitivity to Radiation

10.1158/0008-5472.can-21-0384 · 2022 · External reference

Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells

10.1038/s41375-021-01476-y · 2022 · External reference

Differential impact of IDH1 /2 mutational subclasses on outcome in adult AML: results from a large multicenter study

10.1182/bloodadvances.2021004934 · 2022 · External reference

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study

10.1182/blood.2020010165 · 2021 · External reference

Mutant IDH1 cooperates with NPM1c or FLT3(ITD) to drive distinct myeloid diseases and molecular outcomes

10.1073/pnas.2415779122 · 2025 · External reference

Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines

10.18632/oncotarget.3723 · 2015 · External reference

Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells

2015 · External reference

Enchondroma

2020 · External reference

Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1

10.1073/pnas.1708914114 · 2017 · External reference

Loss of IDH1 and IDH2 mutations during the evolution of metastatic chondrosarcoma

10.1186/s13059-025-03812-2 · 2025 · External reference

The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo

10.18632/oncotarget.4024 · 2015 · External reference